Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 September 2022 | Story NONSINDISO QWABE | Photo UFS Photo Gallery
UFS Qwaqwa Campus
The UFS Qwaqwa Campus.

Recent global happenings have challenged communities and humanity’s capability to solve immediate and major problems. Science has been one of the spaces in which the communities have looked for solutions regarding real threats to lives related to climate change, wars, as well as social and health pandemics. The Qwaqwa Campus will be showcasing Qwaqwa Campus research and scholarship at this year’s research conference, a two-day event which will be held in person, on 29-30 September 2022 at the Senate Hall on campus.

‘Scholarship, Innovation and Science: how can research be used as a tool for the betterment of society?’

Under this theme, the conference will be a space for intellectual debate and the processing of scholarship in innovation, said Prof Pearl Sithole, Vice-Principal: Academic and Research. “Some of the societal challenges have been urgent and pressing, yet some are slow dilemmas shattering the hope of generations for a better future. This conference will present the products of ‘disciplinary and scholarly crafts’, but it also seeks to explore whether science does (or should) have a strategic direction, and perhaps this is what the concept of innovation should entail. It will ponder on whether in the age-old binary between exploratory research and praxis there is a defeating taming of the entrepreneurial edge for the expanse of science in Africa,” she said.

Prof Sithole said the campus would also be launching its research strategy for 2022 to 2026.

Guest speakers include:

• Prof Percy Hlangothi is an Associate Professor of Physical and Polymer Chemistry at the Nelson Mandela University. He is also the inaugural Director of the Centre for Rubber Science and Technology, a research entity in the Faculty of Science at the same institution.

• Mr Lukhona Mnguni is a governance, politics, and development specialist and prolific political analyst specialising in Africa and international relations, as well as a PhD intern at the University of KwaZulu-Natal. He currently serves as the Head of Policy and Research at the Rivonia Circle. His work includes a current affairs analytical show on eNCA dubbed On the Spot with Lukhona Mnguni.

• Prof Dipane Hlalele is a Professor of Education and a C2 NRF-rated researcher. He is a highly rated scholar in inclusive education, critical pedagogy, and educational psychology at the University of KwaZulu-Natal. Prior to joining UKZN as an associate professor in 2017, he was an assistant dean and senior lecturer at the UFS, a college of education lecturer, and a high school deputy principal and teacher. 

To RSVP please click here on or before 19 September 2022.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept